NasdaqGM:HROWPharmaceuticals
Is It Too Late To Look At Harrow Health (HROW) After Its 1-Year 90% Surge?
If you are wondering whether Harrow's share price still reflects fair value or has already run ahead of itself, you are not alone. This article explores that question in more detail.
Harrow recently closed at US$52.78, with returns of 4.4% over 7 days, 18.7% over 30 days, 5.8% year to date, 90.8% over 1 year and a very large gain over 5 years.
Recent news around Harrow has kept investor attention firmly on the stock, with coverage focusing on its position in the pharmaceuticals space and how...